Summary • Pfizer’s stock is up 1.8% to $26.305 during intraday trading, driven by recent collaborative agreements.• Agreements with Adaptive Biotechnologies focus on T-cell receptor discovery and data ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Arbutus Biopharma ( ($ABUS) ) has issued an announcement. On December 11, 2025, Lindsay Androski, CEO of Arbutus Biopharma, presented at Roivant ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of ...

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this ...

Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...